EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION

M. GRAGERA GÓMEZ, C. REDONDO GALÁN, M.D. RIVAS RODRIGUEZ, A. ROJAS ALBARRÁN, A. GIL GARCÍA, J.F. RANGEL MAYORAL.
BADAJOZ UNIVERSITY HOSPITAL, PHARMACY, BADAJOZ, SPAIN

mercedes.gragera@salud-juntaex.es

Background and importance

The rapid emergence of SARS-CoV2 has led to the development of numerous treatments in a short period of time. The need for clinical expertise is vital for better care and follow-up of the hospitalized patient. **Baricitinib and remdesivir** are two treatments that can be used in combination and have been studied in some clinical trials.

Aim and objectives

Describe the **clinical experience** of the baricitinib - remdesivir combination in a tertiary hospital, as well as to analyze the adverse event (AE) profile.

Material and methods

Observational, descriptive, restrospective and multidisciplinary study of all patients treated with baricitinib-remdesivir

January 2020 to September 2021

- ✓ **Clinical history**
- ✓ **Farmatools®**

Adverse events

- **Age**
- **Sex**
- **Comorbidities**
- **Days of hospital stay**
- **Deaths**
- **Compliance with treatment criteria**

Results

Total of patients with baricitinib remdesivir	50
Men	34
Women	16
Average age (years)	66
Median days of hospitalización	10
Deaths	14
Not candidates of treatment	16



Adverse events:

- x 11 infections
- x 4 cardiotoxicity
- x 4 hepatotoxicity
- x 2 vascular events

Treatment was suspended in 4 patients

Of the 16 patients who did not fulfill treatment criteria, 6 presented an AE (37.5%)

Conclusion and relevance

32% of the patients were **not candidates** for treatment → It may increase the number of AEs.
Treatment should be promoted and monitored only in patients who meet the inclusion criteria, which would lead to a much more **efficient and safer pharmacotherapy.**

5PSQ-122